Compare Adecoagro SA (AGRO) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adecoagro SA vs Novartis AG — how do they compare? Adecoagro SA trades at $9.67 (market cap $1.36B), while Novartis AG trades at $152.33 (market cap $295.37B). The key difference: Novartis AG is far larger — about 217.2× Adecoagro SA's market cap, and Adecoagro SA pays the higher dividend (3.15%). Which is the better fit depends on your goals.
| AGRO | NVS | |
|---|---|---|
Market Cap | $1.36B | $295.37B |
Sector | Technology | Health |
52-Week High | $15.25 | $168.62 |
52-Week Low | $7.13 | $119.31 |
Enterprise Value | $3.39B | $336.69B |
Dividend Yield | 3.15% | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGRO trades at $9.45, up 0.96% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported negative net income of -$8.35M for 2025 despite $1.43B revenue, though 2026 projections show potential profitability improvement. Recent acquisition of Caarapó Mill expands operational footprint while analyst consensus leans neutral with 50% hold ratings.
Outlook remains cautious with elevated P/E ratio of 536.67 offset by attractive P/B of 0.79. Key risks include commodity volatility and integration challenges from recent acquisitions. The stock presents value opportunity if 2026 profitability targets are achieved, but requires careful monitoring of earnings trajectory.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adecoagro SA
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
